Use of midazolam in palliative care
| Autor: | Paul McNamara, Michael Minton, Robert G. Twycross |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Benzodiazepine
medicine.medical_specialty Palliative care Psychomotor agitation medicine.drug_class business.industry Terminally ill 030208 emergency & critical care medicine Retrospective cohort study General Medicine medicine.disease 03 medical and health sciences Epilepsy 0302 clinical medicine Anesthesiology and Pain Medicine 030502 gerontology medicine Midazolam medicine.symptom 0305 other medical science Intensive care medicine business Myoclonus medicine.drug |
| Zdroj: | Palliative Medicine. 5:244-249 |
| ISSN: | 1477-030X 0269-2163 |
| Popis: | Objective: To review the use of midazolam (a water-soluble benzodiazepine) in terminally ill patients.Design: A retrospective study of 104 patients.Results: Midazolam was used intravenously as sedation before minor procedures in three patients. Because of prolonged sedation in two patients, the following regimen is now used: 1 mg intravenously stat, followed by 1 mg/min, or 0.5mg/min in those over 65. In other situations, midazolam was used subcutaneously (SC), usually via a syringe driver. For muscle relaxation the median dose was 30mg SC/24h (27 patients; range 10-60mg). When treating terminal agitated delirium the median dose was 35mg SC/24h (61 patients; range 10-240mg). For multifocal myoclonus or as prophylaxis against fits the median dose was 30mg SC/24h (12 patients; range 15-80mg). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|